Cargando…

Profile of Co-Infection Prevalence and Antibiotics Use among COVID-19 Patients

Bacterial co-infection in COVID-19 patients significantly contributes to the worsening of the prognosis based on morbidity and mortality. Information on the co-infection profile in such patients could help to optimize treatment. The purpose of this study was to describe bacterial co-infections assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Greco, Rita, Panetta, Vittorio, Della Rocca, Maria Teresa, Durante, Adriana, Di Caprio, Giovanni, Maggi, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695079/
https://www.ncbi.nlm.nih.gov/pubmed/36365001
http://dx.doi.org/10.3390/pathogens11111250
_version_ 1784837967263563776
author Greco, Rita
Panetta, Vittorio
Della Rocca, Maria Teresa
Durante, Adriana
Di Caprio, Giovanni
Maggi, Paolo
author_facet Greco, Rita
Panetta, Vittorio
Della Rocca, Maria Teresa
Durante, Adriana
Di Caprio, Giovanni
Maggi, Paolo
author_sort Greco, Rita
collection PubMed
description Bacterial co-infection in COVID-19 patients significantly contributes to the worsening of the prognosis based on morbidity and mortality. Information on the co-infection profile in such patients could help to optimize treatment. The purpose of this study was to describe bacterial co-infections associated with microbiological, clinical, and laboratory data to reduce or avoid a secondary infection. A retrospective cohort study was conducted at Sant’Anna and San Sebastiano Hospital from January 2020 to December 2021. Bacterial co-infection was detected in 14.3% of the COVID-19-positive patients. The laboratory findings on admission showed significant alterations in the median D-dimer, C-reactive protein, interleukin-6, and lactate dehydrogenase values compared to normal values. All inflammatory markers were significantly elevated. The most common pathogens isolated from blood cultures were E. faecalis and S. aureus. Instead, the high prevalence of respiratory tract infections in the COVID-19 patients was caused by P. aeruginosa (41%). In our study, 220 (82.4%) of the COVID-19 patients received antimicrobial treatment. Aminoglycosides and β-lactams/β-lactamase inhibitors showed the highest resistance rates. Our results showed that older age, underlying conditions, and abnormal laboratory parameters can be risk factors for co-infection in COVID-19 patients. The antibiotic susceptibility profile of bacterial pathogen infection provides evidence on the importance, for the clinicians, to rationalize and individualize antibiotic usage.
format Online
Article
Text
id pubmed-9695079
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96950792022-11-26 Profile of Co-Infection Prevalence and Antibiotics Use among COVID-19 Patients Greco, Rita Panetta, Vittorio Della Rocca, Maria Teresa Durante, Adriana Di Caprio, Giovanni Maggi, Paolo Pathogens Article Bacterial co-infection in COVID-19 patients significantly contributes to the worsening of the prognosis based on morbidity and mortality. Information on the co-infection profile in such patients could help to optimize treatment. The purpose of this study was to describe bacterial co-infections associated with microbiological, clinical, and laboratory data to reduce or avoid a secondary infection. A retrospective cohort study was conducted at Sant’Anna and San Sebastiano Hospital from January 2020 to December 2021. Bacterial co-infection was detected in 14.3% of the COVID-19-positive patients. The laboratory findings on admission showed significant alterations in the median D-dimer, C-reactive protein, interleukin-6, and lactate dehydrogenase values compared to normal values. All inflammatory markers were significantly elevated. The most common pathogens isolated from blood cultures were E. faecalis and S. aureus. Instead, the high prevalence of respiratory tract infections in the COVID-19 patients was caused by P. aeruginosa (41%). In our study, 220 (82.4%) of the COVID-19 patients received antimicrobial treatment. Aminoglycosides and β-lactams/β-lactamase inhibitors showed the highest resistance rates. Our results showed that older age, underlying conditions, and abnormal laboratory parameters can be risk factors for co-infection in COVID-19 patients. The antibiotic susceptibility profile of bacterial pathogen infection provides evidence on the importance, for the clinicians, to rationalize and individualize antibiotic usage. MDPI 2022-10-28 /pmc/articles/PMC9695079/ /pubmed/36365001 http://dx.doi.org/10.3390/pathogens11111250 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Greco, Rita
Panetta, Vittorio
Della Rocca, Maria Teresa
Durante, Adriana
Di Caprio, Giovanni
Maggi, Paolo
Profile of Co-Infection Prevalence and Antibiotics Use among COVID-19 Patients
title Profile of Co-Infection Prevalence and Antibiotics Use among COVID-19 Patients
title_full Profile of Co-Infection Prevalence and Antibiotics Use among COVID-19 Patients
title_fullStr Profile of Co-Infection Prevalence and Antibiotics Use among COVID-19 Patients
title_full_unstemmed Profile of Co-Infection Prevalence and Antibiotics Use among COVID-19 Patients
title_short Profile of Co-Infection Prevalence and Antibiotics Use among COVID-19 Patients
title_sort profile of co-infection prevalence and antibiotics use among covid-19 patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695079/
https://www.ncbi.nlm.nih.gov/pubmed/36365001
http://dx.doi.org/10.3390/pathogens11111250
work_keys_str_mv AT grecorita profileofcoinfectionprevalenceandantibioticsuseamongcovid19patients
AT panettavittorio profileofcoinfectionprevalenceandantibioticsuseamongcovid19patients
AT dellaroccamariateresa profileofcoinfectionprevalenceandantibioticsuseamongcovid19patients
AT duranteadriana profileofcoinfectionprevalenceandantibioticsuseamongcovid19patients
AT dicapriogiovanni profileofcoinfectionprevalenceandantibioticsuseamongcovid19patients
AT maggipaolo profileofcoinfectionprevalenceandantibioticsuseamongcovid19patients